Title of the cohort
Caerphilly Prospective Cohort study
Acronym for cohort
CaPS
Name of Principal Investigator
| Title | Dr. |
| First name | John |
| Last name | Gallacher |
Address of institution where award is held
| Institution | Department of Primary Care and Public Health |
| Street Address | Heath Park |
| City | Cardiff |
| Postcode | CF14 4XY |
Country
United Kingdom
Website
http://www.epi.bris.ac.uk/caerphilly/caerphilly.htm
Contact email
Funding source
None at the moment
1. The cohort includes, or expects to include, incidence of the following conditions
- Alzheimer’s disease and other dementias
- Parkinson’s disease
When studies on the above condition(s) are expected to become possible
Already possible
2a. Stated aim of the cohort
Was initially set up to examine cardiovascular risk factors but then included cognitive function and other age-related phenotypes
2b. Features distinguishing this cohort from other population cohorts
Long term follow-up and wide range of phenotypes
3a. i) Number of publications that involve use of cohort to date
3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)
3b. Publication list/link to where data or publications are accessible (if available)
3c. Information (i.e. research findings) expected to be gained from the population cohort
4a. Study criteria: age range of participants at recruitment
| Age in years from: | 45 |
| To (‘until death’ if applicable): | 59 |
4b. Study criteria: inclusion criteria
Middle men registered in specific general practices in Caerphilly and surrounding villages
4c. Study criteria: exclusion criteria
None
5. Size of the cohort (i.e. number of participants enrolled)
1,000 – 5,000 participants
6a. Measures used to characterise participants
Mulitple phenotypes
6b. Additional measures for participants with a clinical disorder
No
6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)
Mortality, CVD, stroke, Heart failure, dementia, PD, diabetes, renal failure
7. Study design
- Prospective cohort
8. Cases matched by
- Other health assessment (specify) / N/A
- No matching
9a. Does the study include a specialised subset of control participants
No
9b. If yes, description of specialised subset of control participants
10a. i) Data collection start date
10-07-1979
10a. ii) Data collection end date
10a iii) Data collection for this study is
- Data collection ongoing
10b. Plans to continue the cohort study beyond the current projected end date
- Yes – intend to apply for funding
11. Data collected
- Through links to medical records
12. System in place to enable re-contact with patients for future studies
Yes (participants have given permission to be re-contacted via the PIs to ask if they would participate in further studies)
13a. Format and availability of data stored in a database
| Yes/No | % available | |
| Data summarised in database | Yes | 100 |
| Database is web-based | No | |
| Database on spreadsheet | No | |
| Database is on paper | No | |
| Other (specify) |
Language used:
English
13b. Format and availability of data held as individual records
| Yes/No | % available | |
| Data held as individual records | Yes | 100 |
| Data is web-based | No | |
| Data held on computer based records | Yes | 100 |
| Data held on cards | No | |
| Other (specify) |
Language used:
English
14a. Are data available to other groups
Yes
14b. Access policy/mechanisms for access if data are available to other groups
- Apply to PI or co-ordinator at resource
- Access Committee mechanism
- National access
- International access
- Access to industry
- Access restricted to peer-reviewed work
15. Data sharing policy specified as a condition of use
No requirement to make data publicly available
16a. Are tissues/samples/DNA available to other groups
Yes
16b. i) Description of available tissues/samples/DNA
- Living donors:blood
- Living donors: blood derivatives
- Living donors: DNA
16b. ii) Form available tissues/samples/DNA are supplied in
- Primary Samples: Stabilised samples (frozen or fixed)
- Secondary samples: derivatives of primary samples
- Secondary samples: plasma
- Secondary samples: DNA
16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data
Yes
17. Is information on biological characteristics available to other groups
- Yes, for all the cohort